Pierre Fabre Medicament
Clinical trials sponsored by Pierre Fabre Medicament, explained in plain language.
-
New cell therapy targets Epstein-Barr virus in immune-compromised patients
Disease control OngoingThis study tests an experimental cell therapy called tabelecleucel in 190 people with diseases caused by the Epstein-Barr virus (EBV), including certain lymphomas and post-transplant complications. The treatment uses specially prepared immune cells to fight the virus. The main go…
Phase: PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Oral chemotherapy pill tested for advanced breast cancer
Disease control OngoingThis study looks at how well oral vinorelbine, a chemotherapy pill, works in women with advanced breast cancer. It includes women who have already taken the drug or are starting it now. Researchers track how long the cancer stays under control and how patients feel during treatme…
Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug cocktail targets rare lung cancer mutation in chinese patients
Disease control OngoingThis phase 2 study tests a combination of two targeted drugs, encorafenib and binimetinib, in Chinese patients with advanced non-small cell lung cancer that has a specific BRAF V600E mutation. The goal is to see if the drugs can shrink tumors and control the disease. About 63 pat…
Phase: PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase trial is testing a new drug called KIN-2787 (exarafenib), alone or combined with another drug (binimetinib), in 400 adults with advanced solid tumors that have BRAF or NRAS mutations. The main goals are to check safety, find the best dose, and see if the drug can…
Phase: PHASE1 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC